Group One Trading
NVCR icon

Group One Trading’s NovoCure NVCR Stock Holding History

Group One Trading’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32.7K Sell
3,000
-26,800
-90% -$335K ﹤0.01% 5594
2025
Q4 		$385K Sell
29,800
-6,200
-17% -$79.6K ﹤0.01% 3774
2025
Q3 		$465K Buy
36,000
+28,900
+407% +$386K ﹤0.01% 3786
2025
Q2 		$126K Sell
7,100
-17,100
-71% -$298K ﹤0.01% 4758
2025
Q1 		$431K Buy
24,200
+3,600
+17% +$81.8K ﹤0.01% 3247
2024
Q4 		$614K Sell
20,600
-2,200
-10% -$46.6K ﹤0.01% 3001
2024
Q3 		$356K Buy
22,800
+6,600
+41% +$120K ﹤0.01% 3112
2024
Q2 		$278K Sell
16,200
-4,100
-20% -$72.1K ﹤0.01% 3110
2024
Q1 		$317K Sell
20,300
-396,200
-95% -$5.83M ﹤0.01% 3171
2023
Q4 		$6.22M Buy
416,500
+394,800
+1,819% +$5.28M 0.02% 969
2023
Q3 		$350K Sell
21,700
-59,300
-73% -$1.71M ﹤0.01% 3281
2023
Q2 		$3.36M Buy
81,000
+17,500
+28% +$1.09M 0.01% 1277
2023
Q1 		$3.82M Sell
63,500
-113,500
-64% -$9.07M 0.01% 1015
2022
Q4 		$13M Buy
177,000
+81,300
+85% +$6.12M 0.03% 595
2022
Q3 		$7.27M Buy
95,700
+23,000
+32% +$1.79M 0.01% 914
2022
Q2 		$5.05M Sell
72,700
-8,200
-10% -$618K 0.01% 1282
2022
Q1 		$6.7M Sell
80,900
-35,000
-30% -$2.58M 0.01% 1303
2021
Q4 		$8.7M Buy
115,900
+15,800
+16% +$1.59M 0.01% 1214
2021
Q3 		$11.6M Buy
100,100
+26,500
+36% +$4.01M 0.01% 968
2021
Q2 		$16.3M Buy
73,600
+25,000
+51% +$4.86M 0.02% 752
2021
Q1 		$6.42M Buy
48,600
+12,800
+36% +$2.02M 0.01% 1300
2020
Q4 		$6.2M Sell
35,800
-3,100
-8% -$424K 0.01% 1133
2020
Q3 		$4.33M Buy
38,900
+15,000
+63% +$1.2M 0.01% 1013
2020
Q2 		$1.42M Buy
23,900
+9,500
+66% +$625K 0.01% 1729
2020
Q1 		$970K Buy
14,400
+9,600
+200% +$759K 0.01% 1550
2019
Q4 		$405K Sell
4,800
-27,100
-85% -$2.19M ﹤0.01% 2613
2019
Q3 		$2.38M Sell
31,900
-14,900
-32% -$1.19M 0.02% 1071
2019
Q2 		$2.96M Buy
46,800
+40,400
+631% +$2.05M 0.03% 825
2019
Q1 		$308K Sell
6,400
-800
-11% -$38.5K ﹤0.01% 2360
2018
Q4 		$241K Sell
7,200
-3,900
-35% -$143K ﹤0.01% 2534
2018
Q3 		$582K Buy
11,100
+8,700
+363% +$346K ﹤0.01% 2152
2018
Q2 		$75K Sell
2,400
-1,200
-33% -$33.4K ﹤0.01% 3725
2018
Q1 		$78K Buy
3,600
+200
+6% +$4.3K ﹤0.01% 3403
2017
Q4 		$69K Sell
3,400
-500
-13% -$9.63K ﹤0.01% 3558
2017
Q3 		$77K Buy
3,900
+1,000
+34% +$19.7K ﹤0.01% 3395
2017
Q2 		$50K Buy
2,900
+700
+32% +$9.04K ﹤0.01% 3509
2017
Q1 		$18K Buy
2,200
+1,700
+340% +$12.3K ﹤0.01% 3914
2016
Q4 		$4K Sell
500
-10,900
-96% -$87.7K ﹤0.01% 4147
2016
Q3 		$97K Buy
11,400
+10,700
+1,529% +$97.6K ﹤0.01% 2943
2016
Q2 		$8K Buy
+700
New +$8.76K ﹤0.01% 4147

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Group One Trading's NVCR Position: Q1 2026 in Review

Group One Trading sold out of NovoCure (NVCR) in Q1 2026, closing a stake of 22,597 shares — an estimated $282K sold.

Group One Trading first reported a position in NVCR in Q4 2015 and held it in 18 quarters. The position peaked at $3.71M in Q4 2021. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • Group One Trading reported no remaining NovoCure position as of Q1 2026 after selling out during the quarter.
  • Group One Trading sold 22,597 NovoCure shares in Q1 2026, an estimated $282K.
  • Group One Trading first reported a position in NovoCure in Q4 2015 and held it in 18 quarters.
  • Group One Trading's NovoCure position peaked at $3.71M in Q4 2021.
  • 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.